Adelphi Group

adelphigroup.com

The Adelphi Group provides a wide range of strategic support services and consulting for global pharmaceutical clients. Adelphi is dedicated to the healthcare sector, providing services across strategic marketing, marketing and business intelligence, real-world observational research and disease-specific programmes, health and economic outcomes, market access, pricing and reimbursement, value insight, multi-channel health communications, scientific services, medical education, and strategic product

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

PARTEK AND AGILENT PARTNER TO DELIVER ALISSA CUSTOMERS END-TO-END BIOINFORMATICS WORKFLOW

Partek® Incorporated | August 20, 2021

news image

Partek® Incorporated announced today they have entered into an agreement with Agilent to integrate Partek® Flow® bioinformatics software with the Agilent Alissa Clinical Informatics Platform. This integration delivers a complete end-to-end analysis workflow that is robust, flexible, and customizable to meet Agilent customer demands. Partek has also made available the Agilent pipeline for RNA-Seq inside Partek Flow. In addition, the agreement allows Agilent to resell Partek Flow softw...

Read More

INDUSTRIAL IMPACT

UNITY BIOTECHNOLOGY ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH JOCASTA NEUROSCIENCE TO CONTINUE DEVELOPMENT OF Α-KLOTHO PROGRAM

UNITY | December 21, 2021

news image

UNITY Biotechnology, Inc. a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, announced it has signed an exclusive agreement licensing its α-Klotho asset to Jocasta Neuroscience, Inc. for development and commercialization. The α-Klotho protein is a circulating factor associated with improved cognitive performance in preclinical studies. α-Klotho is hypothesized to optimize synaptic neurotransmission of N-methyl-D-aspartate...

Read More

MEDICAL

TAIWAN STARTUP MOLSENTECH ULTRA-HIGH SENSITIVITY BIOMEDICAL DETECTION TECHNOLOGY LEAPS ONTO GLOBAL STAGE

Molsentech | July 29, 2022

news image

With its impressive achievements, Molsentech has been selected by the TTA Global Challenge sponsored by Taiwan's Ministry of Science and Technology to participate in US BIO 2022, poised to leverage its introduction to the US market as a stepping stone to leap further into the global stage. The company has successfully launched an electrical based detection system employing ultra-high sensitivity biomedical detection technology that can be applied in various disease detection from an early st...

Read More

INDUSTRIAL IMPACT

GILEAD SCIENCES TO ACQUIRE MIROBIO

Gilead Sciences, Inc. | August 05, 2022

news image

Gilead Sciences, Inc. and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and entire portfolio of imm...

Read More
news image

INDUSTRIAL IMPACT

PARTEK AND AGILENT PARTNER TO DELIVER ALISSA CUSTOMERS END-TO-END BIOINFORMATICS WORKFLOW

Partek® Incorporated | August 20, 2021

Partek® Incorporated announced today they have entered into an agreement with Agilent to integrate Partek® Flow® bioinformatics software with the Agilent Alissa Clinical Informatics Platform. This integration delivers a complete end-to-end analysis workflow that is robust, flexible, and customizable to meet Agilent customer demands. Partek has also made available the Agilent pipeline for RNA-Seq inside Partek Flow. In addition, the agreement allows Agilent to resell Partek Flow softw...

Read More
news image

INDUSTRIAL IMPACT

UNITY BIOTECHNOLOGY ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH JOCASTA NEUROSCIENCE TO CONTINUE DEVELOPMENT OF Α-KLOTHO PROGRAM

UNITY | December 21, 2021

UNITY Biotechnology, Inc. a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, announced it has signed an exclusive agreement licensing its α-Klotho asset to Jocasta Neuroscience, Inc. for development and commercialization. The α-Klotho protein is a circulating factor associated with improved cognitive performance in preclinical studies. α-Klotho is hypothesized to optimize synaptic neurotransmission of N-methyl-D-aspartate...

Read More
news image

MEDICAL

TAIWAN STARTUP MOLSENTECH ULTRA-HIGH SENSITIVITY BIOMEDICAL DETECTION TECHNOLOGY LEAPS ONTO GLOBAL STAGE

Molsentech | July 29, 2022

With its impressive achievements, Molsentech has been selected by the TTA Global Challenge sponsored by Taiwan's Ministry of Science and Technology to participate in US BIO 2022, poised to leverage its introduction to the US market as a stepping stone to leap further into the global stage. The company has successfully launched an electrical based detection system employing ultra-high sensitivity biomedical detection technology that can be applied in various disease detection from an early st...

Read More
news image

INDUSTRIAL IMPACT

GILEAD SCIENCES TO ACQUIRE MIROBIO

Gilead Sciences, Inc. | August 05, 2022

Gilead Sciences, Inc. and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and entire portfolio of imm...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us